49. 全身性エリテマトーデス [臨床試験数:827,薬物数:638(DrugBank:168),標的遺伝子数:108,標的パスウェイ数:191

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
20 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03492255April 12, 201816/3/2018CYCLONES - CYClophosphamide LOw Dose and No Extra SteroidCYCLONES - CYClophosphamide LOw Dose and No Extra SteroidSystemic Lupus Erythematosus (SLE)Drug: Cyclophosphamide;Drug: Methylprednisolone;Drug: Prednisone;Drug: Mycophenolate MofetilUniversity of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloRecruiting18 YearsN/AAll232N/ABrazil
2NCT03030976March 201722/1/2017A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With CD19+ B Cell Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus (SLE)Drug: cyclophosphamide;Drug: anti-CD19-CAR-T cellsShanghai GeneChem Co., Ltd.RenJi HospitalRecruiting18 Years69 YearsAll5Phase 1China
3NCT02080195September 13, 201628/2/2014Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLELupus Erythematosus;Graft-versus-host DiseaseDrug: Cyclophosphamide;Drug: Fludarabine;Drug: Tacrolimus;Drug: Mycophenolate Mofetil;Drug: Rabbit antithymocyte globulin;Radiation: Total body irradiation;Biological: Allogeneic bone marrow transplantSidney Kimmel Comprehensive Cancer Center at Johns HopkinsMaryland Stem Cell Research FundTerminated18 Years75 YearsAll1Phase 1/Phase 2United States
4ChiCTR-ONC-150075472015-12-052015-12-04Clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus: a multicenter prospective cohort studyStudy of the clinical theraputic effect of traditional Chinese medicine on systemic lupus erythematosus systemic lupus erythematosusThe combination of Chinese and western group:Traditional Chinese medicine combined western medicine;Treating by Western Medicine group:Treating by Western medicine (sugar cortical hormone, hydroxychloroquine, and methotrexate, azathioprine, or cyclophosphamide);Zhejiang Chinese Medical UniversityNULLRecruiting1860BothThe combination of Chinese and western group:264;Treating by Western Medicine group:264;China
5NCT02444728July 201512/5/2015Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLECyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus ErythematosusThrombocytopeniaDrug: Hydroxychloroquine;Drug: Cyclophosphamide;Drug: Azathioprine;Drug: MethylprednisoloneChinese SLE Treatment And Research GroupPeking Union Medical College HospitalRecruiting18 Years70 YearsAll220Phase 3China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01060410May 20101/2/2010Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus TreatmentExploration of Genetic Polymorphisms Related to Individual Variations of Side Effects of Cyclophosphamide in Systemic Lupus Erythematosus TreatmentLupus Erythematosus, Systemic;Adverse EffectsGenetic: Polymorphism Analysis;Drug: Cyclophosphamide;Other: Pharmacokinetic analysisSun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen UniversityCompleted12 Years80 YearsBoth222N/AChina
7NCT00626197February 200820/2/2008A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus ErythematosusLupus Nephritis;Systemic Lupus ErythematosusDrug: corticosteroids;Drug: cyclophosphamide;Drug: mycophenolate mofetil;Drug: ocrelizumab;Drug: placeboGenentech, Inc.Roche Pharma AGCompleted16 YearsN/AAll381Phase 3United States
8EUCTR2005-003957-28-DK21/12/200620/11/2006FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMISEDACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILESYSTEMIC LUPUS ERYTHEMATOSUS NEPHRITIS: ORALCYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUSCYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUSCYCLOPHOSPHAMIDEFIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMISEDACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILESYSTEMIC LUPUS ERYTHEMATOSUS NEPHRITIS: ORALCYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUSCYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUSCYCLOPHOSPHAMIDE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHRITIS
MedDRA version: 8.1Level: LLTClassification code 10029142Term: Nephritis systemic lupus erythematosus
Product Name: Cyclophosphamide
Product Name: Cyclophosphamide
Istituto Giannina GasliniNULLNot RecruitingFemale: yes
Male: yes
141Phase 3Denmark;Italy
9NCT00336414June 200612/6/2006Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus NephritisFive-Year Single-Blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis: Oral Cyclophosphamide Versus High Dose Intravenous Cyclophosphamide Versus Intermediate Dose Intravenous CyclophosphamideSystemic Lupus Erythematosus NephritisDrug: cyclophosphamide-prednisone-azathioprineIstituto Giannina GasliniNULLWithdrawn1 Year18 YearsAll0Phase 3Italy
10EUCTR2005-003957-28-IT02/05/200609/05/2006FIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. - NDFIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. - ND New onset juvenile sistemic lupus erythematosus nephritis
MedDRA version: 6.1Level: PTClassification code 10025140
INN or Proposed INN: Azathioprine
INN or Proposed INN: Methylprednisolone
INN or Proposed INN: Prednisone
INN or Proposed INN: Cyclophosphamide
INN or Proposed INN: Cyclophosphamide
ISTITUTO GIANNINA GASLININULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
141Phase 2Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00278538September 23, 200515/1/2006Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus ErythematosusCyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II TrialSystemic Lupus ErythematosusBiological: Hematopoietic stem cell transplantationNorthwestern UniversityNULLCompleted15 Years60 YearsAll32Phase 2United States
12NCT00094380September 200416/10/2004Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)Treatment of Systemic Lupus Erythematosus With CTLA4-IgG4m Plus Cyclophosphamide: A Phase I/IIA StudyLupus Erythematosus, Systemic;Lupus NephritisDrug: CTLA4-IgG4m (RG2077);Drug: CyclophosphamideNational Institute of Allergy and Infectious Diseases (NIAID)Immune Tolerance Network (ITN)Completed18 YearsN/AAll6Phase 1/Phase 2United States
13NCT00076752January 30, 20042/2/2004Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus ErythematosusA Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus ErythematosusLupus Erythematosus, SystemicDrug: fludarabine phosphate;Drug: cyclophosphamide;Biological: Rituxan (rituximab);Biological: filgrastim;Drug: methylprednisolone;Other: immunologic technique;Other: laboratory biomarker analysis;Procedure: autologous hematopoietic stem cell transplantation;Drug: Diphenhydramine;Drug: MesnaNational Cancer Institute (NCI)NULLCompleted15 Years40 YearsAll9Phase 2United States
14NCT00976300January 200211/9/2009Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune StudyCyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune StudySystemic Lupus Erythematosus;Lupus NephritisDrug: Cyclosporine A;Drug: CyclophosphamideInstitute of Rheumatology, PragueMinistry of Health, Czech Republic;Charles University, Czech Republic;Palacky University;Department of Rheumatology, Hospital, Ceske Budejovice, Czech Republic;National Institute of Rheumatology, Piestany, Slovakia;Faculty Hospital St. Anna, BrnoCompleted18 Years70 YearsBoth40Phase 2Czech Republic
15NCT00017641April 20016/6/2001Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: filgrastim;Procedure: CD34+ Peripheral Blood Stem Cell ReinfusionNorthwestern Memorial HospitalNULLActive, not recruitingN/A59 YearsBoth10Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00006055March 20005/7/2000Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNULLActive, not recruiting1 Year55 YearsBoth10N/AUnited States
17NCT00001676January 19983/11/1999Cyclophosphamide and Fludarabine to Treat Lupus NephritisCombination of Cyclophosphamide and Fludarabine for Lupus Nephritis: Tolerance, Toxicity, Efficacy and Effects on B and T Lymphocyte RegenerationGlomerulonephritis;Lupus Nephritis;Systemic Lupus ErythematosusDrug: SQ FludarabineNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NULLCompletedN/AN/ABoth15Phase 1United States
18NCT00010400April 19972/2/2001Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody SyndromeSystemic Lupus Erythematosus;Antiphospholipid Antibody SyndromeDrug: Cyclophosphamide;Drug: filgrastimJohns Hopkins UniversityNULLCompleted18 Years70 YearsBoth35N/AUnited States
19NCT00001212November 19863/11/1999Drug Therapy in Lupus NephropathyImmunosuppressive Drug Therapy in Membranous Lupus NephropathyNephrotic Syndrome;Systemic Lupus ErythematosusDrug: prednisone;Drug: cyclophosphamide;Drug: cyclosporin ANational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompletedN/AN/ABoth45Phase 2United States
20EUCTR2005-003957-28-BE24/10/2006Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile systemic lupus erythematosus nephritis: oral cyclophosphamide versus high dose intravenous cyclophosphamide versus intermediate dose intravenous cyclophosphamide - PRINTO JSLE TrialFive year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile systemic lupus erythematosus nephritis: oral cyclophosphamide versus high dose intravenous cyclophosphamide versus intermediate dose intravenous cyclophosphamide - PRINTO JSLE Trial Systemic lupus erythematosus nephritisProduct Name: Azathioprine
INN or Proposed INN: Azathioprine
Product Name: Methylprednisolone
INN or Proposed INN: Methylprednisolone sodium succinate
Product Name: Prednisolone
INN or Proposed INN: Methylprednisolone
Product Name: Cyclophosphamide
INN or Proposed INN: Cyclophosphamide
Product Name: Cyclophosphamide
INN or Proposed INN: Cyclophosphamide
University Hospital GentNULLNAFemale: yes
Male: yes
216Phase 3Belgium;Denmark;Italy